Drugs / ZSP1603
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03619616 | Jul 2018 → Jun 2019 | idiopathic pulmonary fibrosis, neoplasm | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05119972 | Oct 2021 → Dec 2023 | idiopathic pulmonary fibrosis | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSP1603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03619616 ↗ |
| Route | Oral | “administered orally” NCT03619616 ↗ |